Background: A major challenge in managing left-sided infective endocarditis (LSIE) is identifying patients who will benefit from surgery including those with prohibitive operative risk. However, no widely validated models are currently available to estimate 30-day mortality early after the initial diagnostic evaluation in the broader LSIE population including patients managed without surgery. We aimed to develop and externally validate the European Infective Endocarditis (EURO-ENDO) risk score for predicting 30-day mortality in patients with LSIE. Methods: The prospective, multicentre European Society of Cardiology (ESC)-EURObservational Research Programme EURO-ENDO registry included 2171 patients with LSIE diagnosed according to ESC 2015 criteria. Clinical, biological, microbiological and imaging variables were analysed and a multivariable logistic regression model was developed. Internal validation was performed using bootstrap resampling. External validation was conducted in an independent temporal cohort of 377 consecutive patients with LSIE from two tertiary centres in Barcelona, Spain, recruited between 2019 and 2024. Results: Among 2140 registry patients included in the final analysis, 254 (11.9%) died within 30 days. Eleven variables were independently associated with 30-day mortality and included in the EURO-ENDO prediction model: previous stroke or transient ischaemic attack, previous cardiac surgery, heart failure or cardiogenic shock, creatinine >2 mg/dL, vegetations >10 mm, severe regurgitation, abscess, negative blood cultures, Staphylococcus aureus infection, absence of surgical indication and surgical indication without intention to operate. The model showed good discrimination and calibration (area under the receiver operating characteristic (AUROC) 0.763; Hosmer-Lemeshow p=0.825; Brier score 0.09). In the external validation cohort, 48/377 patients (12.7%) died; discrimination remained excellent (AUROC 0.799; 95% CI 0.730 to 0.868) with good calibration (slope 1.017; expected-to-observed ratio 1.124). Conclusions: The EURO-ENDO risk score, incorporating 11 variables available during the initial diagnostic evaluation, accurately predicts individualised 30-day mortality in patients with LSIE and showed consistent performance in both internal and external validation cohorts. This tool may support early risk stratification, multidisciplinary endocarditis team discussions and clinical decision-making ( https://scoreei.web.app/score ).
Sutureless aortic bioprostheses have become an established alternative for surgical aortic valve replacement, particularly in elderly and high-risk patients. The Perceval (Livanova) valve, the most widely studied sutureless device, offers favorable hemodynamic performance and reduced operative times but introduces specific challenges when prosthetic valve endocarditis (PVE) occurs. Although the incidence of Perceval PVE is low and comparable to that of conventional bioprostheses, this complication is associated with substantial morbidity and mortality. Diagnosis is often complex due to acoustic shadowing on echocardiography, making multimodality imaging with transesophageal echocardiography, cardiac computed tomography, and [18F]-FDG PET/CT essential. Microbiological profiles resemble those of other biological prostheses, but perivalvular extension and early mechanical instability are frequent. Management follows general PVE principles but often requires early surgical intervention because of the valve’s reliance on radial fixation. This review summarizes current evidence on epidemiology, microbiology, diagnostic strategies, treatment, and prognosis of endocarditis involving the Perceval valve, and identifies areas for future research.
Thoracic and abdominal aortic aneurysms (TAA and AAA) progress silently, and no drug has been shown to slow their growth. Circulating lipids, statins, and metformin are candidate disease modifiers, but the evidence is heterogeneous and largely observational. We searched MEDLINE, Embase, and the Cochrane Library from inception to 24 March 2025, with an update of MEDLINE to 3 October 2026, for randomized and cohort studies of adults with established AAA or TAA. Aneurysm growth was standardized to mm/year and pooled with random-effects models when at least three comparable studies were available. Risk of bias and certainty of evidence were assessed with ROBINS-I and GRADE. Thirty-three studies were included, 32 observational and one randomized; fewer than 20% of participants were women. Circulating lipid fractions showed no consistent association with aneurysm growth. Statin use was associated with slower growth (mean difference −0.78 mm/year; 95% CI −1.13 to −0.43; I2 = 92.4%; 95% prediction interval −2.02 to 0.46 mm/year), lower all-cause mortality, and fewer aortic complications. In AAA, metformin use was associated with slower growth in observational studies (−0.34 mm/year; 95% CI −0.48 to −0.20; I2 = 46.3%), while the single randomized trial found no difference. Certainty of evidence was low to very low. In these largely observational data, aneurysm progression was more closely related to statin and metformin use than to circulating lipid levels, a pattern that is hypothesis-generating and from which causality cannot be inferred.